Page last updated: 2024-08-23

tobramycin and ptc 124

tobramycin has been researched along with ptc 124 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Almstead, NG; Babiak, J; Barton, ER; Branstrom, AA; Campbell, JA; Chen, G; Colacino, JM; Conn, MM; Corson, D; Feng, H; Friesen, WJ; He, F; Hedrick, J; Hirawat, S; Hwang, S; Jacobson, A; Jones, S; Ju, WD; Karp, G; Kawana, M; Khan, A; Miller, LL; Mollin, A; Moon, YC; Northcutt, VJ; Patel, M; Paushkin, S; Peltz, SW; Ren, H; Risher, N; Spatrick, P; Sweeney, HL; Takasugi, J; Tomizawa, Y; Trifillis, P; Trotta, CR; Turpoff, AA; Weetall, M; Welch, EM; Wilde, RG; Yeh, S; Zhuo, J	1
Accurso, FJ; Ajayi, T; Barth, J; Branstrom, A; Bronsveld, I; De Boeck, K; Elborn, JS; Elfring, GL; Fajac, I; Kerem, E; Knoop, C; Konstan, MW; Malfroot, A; McColley, SA; Melotti, P; Peltz, SW; Quattrucci, S; Rietschel, E; Rosenbluth, DB; Rowe, SM; Sermet-Gaudelus, I; Spiegel, RJ; Walker, PA; Welch, EM; Wilschanski, M; Zeitlin, PL	1
Aslam, AA; Higgins, C; Sinha, IP; Southern, KW	1

Reviews

1 review(s) available for tobramycin and ptc 124

Article	Year
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. The Cochrane database of systematic reviews, 2017, 01-19, Volume: 1 Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Codon, Nonsense; Cystic Fibrosis; Disease Progression; Female; Humans; Male; Middle Aged; Oxadiazoles; Quality of Life; Randomized Controlled Trials as Topic; Tobramycin	2017

Article

Year

The Cochrane database of systematic reviews, 2017, 01-19, Volume: 1

Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Codon, Nonsense; Cystic Fibrosis; Disease Progression; Female; Humans; Male; Middle Aged; Oxadiazoles; Quality of Life; Randomized Controlled Trials as Topic; Tobramycin

2017

Trials

1 trial(s) available for tobramycin and ptc 124

Article	Year
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:7 Topics: Acute Kidney Injury; Adolescent; Adult; Anti-Bacterial Agents; Child; Chlorides; Codon, Nonsense; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Oxadiazoles; Sweat; Tobramycin; Young Adult	2014

Article

Year

Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:7

Topics: Acute Kidney Injury; Adolescent; Adult; Anti-Bacterial Agents; Child; Chlorides; Codon, Nonsense; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Oxadiazoles; Sweat; Tobramycin; Young Adult

2014

Other Studies

1 other study(ies) available for tobramycin and ptc 124

Article	Year
PTC124 targets genetic disorders caused by nonsense mutations. Nature, 2007, May-03, Volume: 447, Issue:7140 Topics: Alleles; Animals; Biological Availability; Codon, Nonsense; Dystrophin; Genetic Diseases, Inborn; Humans; Mice; Mice, Inbred mdx; Oxadiazoles; Phenotype; Protein Biosynthesis; RNA, Messenger; Substrate Specificity	2007